Lyons, December 20th, 2010 – For its 7th meeting, BioVision (27-29 March at Lyon in France) will feature
a new platform « business in science » centred on the theme: " The end of the traditional life science
industry model: what's next?"
28 international experts (including CEOs, NGOs and patients’ organisations Directors, Ministers and
European Commissioners) will be considering the future of the traditional model of the life sciences
industry. Among them will be: Zhu Chen (Health Minister, China), Hatem el Gabaly (Health Minister,
Egypt), Charlotte Ersbøll (Corporate VP, Novo Nordisk), Rob ten Hoedt (President, Europe, Medtronic),
Andrew Cassels (Director of strategy, WHO), Philippe Archinard (CEO, Transgene), Elias Zerhouni
(President for worldwide R&D, Sanofi-aventis, Bill & Melinda Gates Foundation, and Professor at the
Collège de France), John A. Thomson (VP, Strategic R&D Networks, Vertex Pharmaceuticals Inc), Olivier
Charmeil (Sr Vice-President Sanofi-aventis), Rajesh Parekh (Director, Head of Healthcare practice Asia,
McKinsey & Company), Antonio Tajani (Vice-president, European Commission), James Geragthy (Sr
Vice-President, Genzyme), André Choulika (Chairman, France Biotech), Anders Olauson (President,
European Patients' Forum), and Michel Goldman (Executive Director, Innovative Medicine Initiative)…
"Business in science" will take the form of 4 round-table discussions on Monday 28th
- How to address the growing challenge of chronic diseases in emerging countries?
- How can technology innovation transform healthcare delivery?
- How to solve R&D's challenge with Open collaborative Innovation?
- Boston, Mumbai, Nairobi..? What is the geographic new deal for boosting innovation in
This track is organised with the support of McKinsey & Company in partnership with Lyon Biopôle and
In addition, and for the first time, a networking software tool will be provided for all registered
attendees interested in organising meetings with other participants (2,500 are expected), a great
opportunity to make the most of their presence at BioVision.
Present at BioVision will be the main life sciences companies (including Royal DSM, Johnson & Johnson
Pharmaceuticals, Novartis, Medtronic, Sanofi-aventis, bioMerieux, Eli Lilly & Company, Vertex
Pharmaceuticals Inc., Genzyme, LFB, Servier, GlaxoSmithKline, Novo Nordisk) as well as major
international companies (including McKinsey & Company, Total Gas and Power, Qualcomm Wireless
Health), and biotechnology companies (including Transgène, Cellectis..). They will all have the
opportunity to meet and mingle with representatives from the main NGOs (including the WHO, Doctors
without Borders, the WWF, Action contre la faim [Action Against Hunger], and The Global Fund), with
large-scale international health organisations (including Roll Back Malaria, the Human Genome
Organisation and the European Patients' forum) and with governments and organisations such as the
European Medicines Agency and the European Food Safety Authority.
For over 10 years, BioVision has been stimulating innovative, high-level debate with all the key stakeholders
(industry, the political sphere, patient associations, etc.) on the societal implications of scientific progress.
Over three days, the leading decision-makers and experts in life sciences will review major scientific advances in
healthcare, nutrition and the environment. They will catalyze discussion between stakeholders (who rarely have
the opportunity to talk to each other) on the impact of these scientific and industrial innovations on society.
BioVision was created in 1999 on the initiative of the late Raymond Barre (a former French Prime Minister and
Vice Chairman of the European Commission) and François Gros (Permanent Secretary of the French Academy of
Sciences). BioVision receives support from major international organisations, the European Commission, local
councils (Lyon City Council, The Lyon Metropolitan Area Council, the Rhône County Council and the Rhône-Alpes
Regional Council) and associations, NGOs and companies dealing with life sciences issues.
For more information, please visit www.biovision.org
Press contacts: Alize PR
Tel.: +33 (0)6 64 18 99 59
Tel.: +33 (0)1 42 68 86 41